Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04658186 · ClinicalTrials.gov registry record · Phase 2
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT04658186 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 496 participants.
The verdict
NCT04658186, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.
Interventions
- DRUG Placebo
- DRUG UCB0599
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04658186
The ClinicalTrials.gov registry entry for NCT04658186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04658186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04658186 about?
NCT04658186 is a clinical study titled "A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease". The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.
What is the current status of trial NCT04658186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2020-12-30. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT04658186?
The interventions under investigation include: Placebo (DRUG), UCB0599 (DRUG).
Who is sponsoring clinical trial NCT04658186?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.